Retinal vein occlusion (RVO) is treated mainly with intravitreal injections, not laser, for the macular swelling it causes. Anti-VEGF drugs (aflibercept, ranibizumab, faricimab) or a slow-release dexamethasone (Ozurdex) implant switch off the leakage and dry the macula. The single biggest factor in how much vision you recover is how early treatment starts, which is why a fast private pathway matters.
What is retinal vein occlusion?
A retinal vein occlusion is a blockage of one of the veins draining the retina, usually where a stiffened artery crosses and compresses a neighbouring vein. The backed-up pressure causes fluid to leak into the macula (macular oedema), blurring and distorting central vision. It is classified by the vein involved: branch RVO (BRVO) affects one sector and generally has a better prognosis, while central RVO (CRVO) blocks the main vein, causes more widespread oedema and carries a higher risk of ischaemic complications such as new-vessel growth and neovascular glaucoma.
RVO is strongly linked to high blood pressure, raised cholesterol, diabetes and glaucoma, so a systemic risk-factor work-up with your GP is a routine part of management. Injections are the same anti-VEGF agents used for wet AMD, and ischaemic complications may need vitreoretinal care.
Treatment options
Treatment is individualised to your occlusion type, the severity of the oedema and how your macula responds on OCT. Most patients start on anti-VEGF; the steroid implant and laser have specific roles.
Where fluorescein angiography shows the retina is ischaemic (loss of blood supply with a risk of fragile new vessels), sectoral or panretinal laser (£600–1,200 per session) is added to treat the ischaemia – injections treat the oedema, laser treats the neovascular risk.
Diagnosed with a retinal vein occlusion? Early treatment recovers more vision – get assessed this week.
Book your assessmentHow the injection works
The injection is an outpatient procedure in a dedicated clean-room suite. After your OCT scan, anaesthetic drops numb the eye and the surface and lids are cleaned with povidone-iodine antiseptic. A small speculum holds the lids open, the drug is injected through the white of the eye a few millimetres behind the cornea (the pars plana safe zone), and the whole thing takes only a few seconds. Most patients feel only brief pressure or a small sting.
Afterwards the eye may feel gritty for a few hours from the antiseptic, and you may notice floaters or a small harmless red patch on the white of the eye – both settle within days. You are given clear warning-symptom advice and a 24/7 emergency contact route, because increasing pain, redness or worsening vision in the days after injection must be reviewed the same day.
The treat-and-extend pathway
Loading phase
Often 3–6 monthly injections to dry the macula, each with an OCT scan to track the fall in macular thickness.
Maintenance
Treat-and-extend: the interval between injections is lengthened in steps while the macula stays dry, and shortened if oedema returns.
Monitoring
OCT at every visit; eye pressure checked (especially after the steroid implant) and the iris/retina watched for new vessels in ischaemic eyes.
Long term
Most patients continue for 1–2 years; some stabilise and stop, others need ongoing maintenance. The fellow eye is monitored and risk factors managed with your GP.
How much does private RVO treatment cost?
RVO treatment is priced per injection because it is delivered as an individualised course. UK 2026 self-pay fees are approximately £900–1,600 per anti-VEGF injection (aflibercept or ranibizumab), £1,100–1,700 for faricimab (Vabysmo), and £1,200–1,900 for a dexamethasone (Ozurdex) implant lasting 3–4 months. The initial medical-retina consultation with OCT is £250–400 and angiography £200–450. Because the number of injections depends on your occlusion type and response, ask for a written first-year cost projection rather than a single-injection headline.
Because RVO is a genuine medical condition, it is generally covered by Bupa, AXA Health, Aviva, Vitality and WPA subject to policy limits and pre-authorisation. See injection pricing or related macular degeneration treatment.
Retinal vein occlusion FAQs
How much does private RVO injection treatment cost in the UK in 2026?
UK 2026 self-pay RVO treatment is priced per injection because it is delivered as an individualised course. Anti-VEGF injections of aflibercept or ranibizumab are typically £900–1,600 each, faricimab (Vabysmo) is £1,100–1,700, and a dexamethasone (Ozurdex) implant lasting 3–4 months is £1,200–1,900. The initial medical-retina consultation with OCT is £250–400 and fluorescein angiography or OCT-angiography £200–450. Because the number of injections depends on your occlusion type and how your macula responds, ask for a written first-year cost projection rather than relying on a single-injection headline price.
How many injections will I need for retinal vein occlusion?
The number is individualised and depends on whether you have a branch (BRVO) or central (CRVO) occlusion, the severity of the macular oedema and how your eye responds. A typical pathway is a loading phase of monthly injections – often three to six – to dry the macula, followed by a treat-and-extend maintenance regime in which the interval between injections is gradually lengthened for as long as the macula stays dry on OCT. Many patients need ongoing treatment over one to two years; some eyes become stable and stop, while others need long-term maintenance. CRVO generally needs more intensive treatment and closer monitoring than BRVO.
What is the difference between BRVO and CRVO?
Retinal vein occlusion is classified by which vein is blocked. Branch retinal vein occlusion (BRVO) blocks one tributary vein and affects only a sector of the retina; it is the more common form and generally has a better visual prognosis. Central retinal vein occlusion (CRVO) blocks the main central retinal vein that drains the entire retina, tends to produce more severe and widespread macular oedema, and carries a higher risk of ischaemic and neovascular complications such as new-vessel growth and neovascular glaucoma. Both are treated primarily with intravitreal injections, but CRVO typically needs more intensive treatment, closer monitoring and a lower threshold for adding laser if the eye is ischaemic.
Anti-VEGF injection or Ozurdex steroid implant – which is better?
Both are effective for RVO macular oedema and the choice is individualised. Anti-VEGF agents (aflibercept, ranibizumab and the dual-action faricimab) are usually first-line: they have an excellent safety profile and strong trial evidence, but they require frequent visits during the loading phase. The Ozurdex dexamethasone implant is a slow-release steroid lasting around three to four months, so it needs fewer visits, which suits patients who cannot attend monthly or who respond poorly to anti-VEGF. Its trade-offs are that it accelerates cataract in eyes that still have their natural lens and can raise eye pressure in steroid-responders, so it needs pressure monitoring. Many patients are managed with anti-VEGF first and switched to, or combined with, the steroid implant if the response is inadequate.
Does the injection hurt?
The injection is performed under local anaesthetic drops, and most patients feel only a brief sensation of pressure or a small sting; the injection itself takes only a few seconds. The eye and eyelids are cleaned thoroughly with antiseptic (povidone-iodine) beforehand, and it is this antiseptic, rather than the needle, that most often causes a gritty feeling for a few hours afterwards, easily soothed with lubricating drops. You may also notice floaters and a harmless red patch on the white of the eye at the injection site, both of which settle within days. Most patients find the procedure far more comfortable than they expected and quickly get used to the routine.
Is retinal vein occlusion treatment urgent?
RVO treatment is time-sensitive even though it is not usually an emergency like a retinal detachment. The macula recovers far better from oedema treated early than from chronic, long-standing swelling, so being assessed, scanned and started on treatment within days to a few weeks materially improves the likely visual outcome. Some situations within RVO are genuine emergencies: a sudden severe drop in vision, or a red painful eye with a fixed dilated pupil, can indicate neovascular glaucoma in an ischaemic CRVO and needs same-day assessment. If you have been told you have an RVO, do not wait – prompt specialist assessment protects vision.